We aimed to assess the efficacy and safety of low-dose propranolol for treatment of infantile hemangiomas (IHs) in China. Our prospective study included data from 89 patients with IH, aged 1–12 months. Plasma renin activity, angiotensin II, and aldosterone were measured before initiation of propranolol therapy. Patients were administered propranolol (0.75–1 mg/kg/day) under close observation. The volume, texture, and color of lesions were used to evaluate efficacy. Safety endpoints included heart rate, systolic and diastolic blood pressures, alanine transaminase, aspartate transaminase, thyroid function tests, and fasting blood glucose. Adverse effects were recorded. Mean plasma angiotensin II concentration in patients with IH was higher than that in age-matched healthy children, whereas mean plasma renin activity was lower. Mean aldosterone level was higher at 1–3 months but lower at 4–12 months, than values reported previously. After propranolol therapy for 6 months, IH regression was classed as grade IV in 44 patients (49.4 %), grade III in 21 patients (23.6 %), and grade II in 24 patients (27.0 %); none were grade I. Mild adverse effects, including diarrhea, restless sleep, nausea, cold extremities, and hypoglycemia, occurred in 12 patients (13.5 %). Slight decreases in heart rate and blood pressure occurred in all patients (p < 0.05). The IHs of four patients (4.5 %) relapsed after treatment cessation at 4–5 months. Conclusion: Low-dose propranolol is effective and safe for Chinese children with IH, and larger-scale studies are merited. Mechanisms underlying IH pathogenesis, and possible involvement of the renin–angiotensin–aldosterone system, deserve study.
This research was supported by the Bureau Level Research Project of Shanghai Municipal Health Bureau (20114020).
Conflict of interest
The authors declare that they have no conflicts of interest.
Achauer BM, Chang CJ, Vander Kam VM (1997) Management of hemangioma of infancy: review of 245 patients. Plast Reconstr Surg 99:1301–1308PubMedCrossRefGoogle Scholar
Chik KK, Luk CK, Chan HB, Tan HY (2010) Use of propranolol in infantile haemangioma among Chinese children. Hong Kong Med J 16:341–346PubMedGoogle Scholar
Denoyelle F, Leboulanger N, Enjolras O, Harris R, Roger G, Garabedian EN (2009) Role of propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol 73:1168–1172PubMedCrossRefGoogle Scholar
Fiselier TJ, Lijnen P, Monnens L, van Munster P, Jansen M, Peer P (1983) Levels of renin, angiotensin I and II, angiotensin-converting enzyme and aldosterone in infancy and childhood. Eur J Pediatr 141:3–7PubMedCrossRefGoogle Scholar
Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA et al (2007) Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 150:291–294PubMedCrossRefGoogle Scholar
Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA et al (2006) Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 118:882–887PubMedCrossRefGoogle Scholar
Holmes WJ, Mishra A, Gorst C, Liew SH (2011) Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg 64:445–451PubMedCrossRefGoogle Scholar
Hsu TC, Wang JD, Chen CH, Chang TK, Wang TM, Chou CM et al (2012) Treatment with propranolol for infantile hemangioma in 13 Taiwanese newborns and young infants. Pediatr Neonatol 53:125–132PubMedCrossRefGoogle Scholar
Itinteang T, Brasch HD, Tan ST, Day DJ (2011) Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg 64:759–765PubMedCrossRefGoogle Scholar
Kent AL, Kecskes Z, Shadbolt B, Falk MC (2007) Blood pressure in the first year of life in healthy infants born at term. Pediatr Nephrol 22:1743–1749PubMedCrossRefGoogle Scholar
Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358:2649–2651PubMedCrossRefGoogle Scholar
Lv MM, Fan XD, Su LX (2012) Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients. Int J Pediatr Otorhinolaryngol 76:574–578PubMedCrossRefGoogle Scholar
Menezes MD, McCarter R, Greene EA, Bauman NM (2011) Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. Ann Otol Rhinol Laryngol 120:686–695PubMedGoogle Scholar
Qin ZP, Liu XJ, Li KL, Zhou Q, Yang XJ, Zheng JW (2009) Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety. Zhonghua Yi Xue Za Zhi 89:3130–3134PubMedGoogle Scholar
Tan ST, Itinteang T, Leadbitter P (2011) Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg 64:292–299PubMedCrossRefGoogle Scholar
Tan ST, Itinteang T, Leadbitter P (2011) Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. Pediatrics 127:e772–776PubMedCrossRefGoogle Scholar
Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ (1989) Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American Whites. N Engl J Med 320:565–570PubMedCrossRefGoogle Scholar
Zhou HH, Shay SD, Wood AJ (1993) Contribution of differences in plasma binding of propranolol to ethnic differences in sensitivity. Comparison between Chinese and Caucasians. Chin Med J (Engl) 106:898–902Google Scholar
Zhou HH, Wood AJ (1991) Increased suppression of exercise-induced increase in renin by propranolol in Chinese subjects. Clin Pharmacol Ther 50:150–156PubMedCrossRefGoogle Scholar